PomDoctor Ltd. Unsponsored ADR (POM) AI Stock Analysis

• Market Cap: $36.72M
• Dividend Yield: N/A
• Average Volume (3M): 2.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.30
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 156
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): N/A
• Shares Outstanding: 106,192,310
• 10 Day Avg. Volume: 781,994
• 30 Day Avg. Volume: 2,198,746
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $0.29 ▼(-7.10% Downside)

PomDoctor Ltd. is facing significant financial instability, with negative equity and persistent losses being the most critical issues. The technical analysis indicates bearish momentum, further weighing down the stock's prospects. The lack of valuation metrics adds uncertainty to its investment appeal. Overall, the stock is currently a high-risk investment.

Positive Factors

Diversified revenue growth with strong online pharmacy expansion

Sustained top-line growth led by an 83% surge in online pharmacy sales indicates a durable shift toward higher-margin digital channels. Expanding online penetration diversifies distribution, supports recurring revenue, and positions the company to scale sales efficiently as China’s digital drug market grows.

Strategic partnerships and internet-hospital expansion

Deep supplier agreements provide access to patented drugs, favorable terms and performance rebates, strengthening supply-chain control. These structural partnerships reduce intermediary costs, improve product mix and give PomDoctor a durable distribution advantage aligned with healthcare reforms toward digital, patient-centric channels.

Material improvement in free cash flow growth

A 64.8% increase in free cash flow growth signals better cash generation and operational discipline. Over the medium term this can reduce dependence on external financing, fund R&D or network expansion, and improve resilience if the trend continues alongside efforts to convert earnings into positive operating cash flow.

Negative Factors

Negative stockholders' equity and weakened balance sheet

Liabilities exceeding assets and negative equity impair financial flexibility and raise solvency concerns. This structural weakness limits ability to borrow, could trigger covenant or liquidity stress, and constrains strategic options such as M&A or sustained R&D investment without corrective capital actions.

Persistent unprofitability and low margins

Deep negative net margins and slim gross margins point to structural issues in pricing, cost base, or product mix. Unless addressed, sustained losses will erode equity and require ongoing financing, making long-term value creation dependent on meaningful margin expansion or structural shifts in product profitability.

Operating cash flow remains negative; weak cash conversion

Negative operating cash flow and poor conversion of income into cash indicate that reported earnings are not translating into liquidity. This structural cash shortfall increases reliance on external funding, limits reinvestment capacity, and elevates risk if capital markets tighten or cash burn persists.

PomDoctor Ltd. Unsponsored ADR Business Overview & Revenue Model

Company Description

Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company's business primarily consists of internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company was founded in 2010 and is headquartered in Guangzhou, China.

How the Company Makes Money

PomDoctor generates revenue through multiple channels, primarily from the sale of its pharmaceutical products and medical devices. The company engages in direct sales to healthcare providers, hospitals, and clinics, which constitute a significant portion of its revenue. Additionally, PomDoctor may enter into licensing agreements with larger pharmaceutical companies for its proprietary technologies, providing a steady stream of royalty income. The company also seeks to expand its earnings through strategic partnerships with research institutions and healthcare organizations, which can lead to joint ventures and collaborative projects in drug development and clinical trials. Government grants and funding for research initiatives further contribute to its financial stability.

PomDoctor Ltd. Unsponsored ADR Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	342.56M	304.85M	245.22M	215.38M
Gross Profit	47.69M	38.72M	54.86M	52.51M
EBITDA	-24.27M	-22.99M	-3.81M	-58.58M
Net Income	-143.36M	-145.39M	-125.51M	-188.40M
Balance Sheet
Total Assets	46.23M	66.31M	48.62M	19.31M
Cash, Cash Equivalents and Short-Term Investments	7.65M	6.72M	2.49M	2.17M
Total Debt	441.10M	413.29M	361.24M	341.26M
Total Liabilities	2.14B	2.03B	1.95B	1.80B
Stockholders Equity	-2.26B	-2.12B	-1.97B	-1.85B
Cash Flow
Free Cash Flow	-16.17M	-45.91M	-22.02M	-15.68M
Operating Cash Flow	-16.13M	-45.80M	-22.02M	-15.68M
Investing Cash Flow	-33.37K	-111.89K	0.00	-500.00K
Financing Cash Flow	17.02M	50.07M	22.49M	5.44M

PomDoctor Ltd. Unsponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PETS	50 Neutral	$74.58M	-1.28	-78.89%	―	-24.81%	-5344.15%
LFMD	49 Neutral	$185.32M	-22.03	―	―	30.71%	73.43%
YI	44 Neutral	$49.79M	-5.11	―	―	-7.46%	73.05%
POM	39 Underperform	$36.72M	―	―	―	―	―

PomDoctor Ltd. Unsponsored ADR Corporate Events

Pomdoctor Deepens Pharma Partnerships to Drive Internet Hospital Expansion in China

On January 16, 2026, Pomdoctor Limited reported significant progress in its strategic collaborations with several leading domestic pharmaceutical companies, including Jiangsu Haosoh Pharmaceutical Group, Xiamen Amoytop Biotech, Shenyang Sinqi Pharmaceutical and Eddingpharm, aimed at accelerating the growth of its internet hospital business in China’s rapidly expanding online drug sales market. These partnerships give Pomdoctor direct access to innovative and patented drugs, favorable purchase terms and performance-based rebates, while providing pharmaceutical manufacturers with a more efficient, data-driven distribution channel that reduces reliance on traditional intermediaries, enhances channel control and supports more targeted marketing. Management framed the model as a “win‑win” supply-chain collaboration that strengthens Pomdoctor’s competitiveness on quality and pricing, broadens product choice for pharmacies and patients, and aligns the company with broader healthcare reforms that are pushing China’s pharmaceutical distribution system toward flatter, more digital and patient‑centric structures.

The most recent analyst rating on (POM) stock is a Sell with a $0.30 price target. To see the full list of analyst forecasts on PomDoctor Ltd. Unsponsored ADR stock, see the POM Stock Forecast page.

Pomdoctor Limited Reports Strong Revenue Growth Amidst Challenging Conditions

Pomdoctor Limited announced its unaudited financial results for the first half of fiscal 2025, ending June 30, 2025. Despite a challenging economic environment, the company reported a 16.2% increase in net revenue, driven by an 83.2% growth in online pharmacy businesses. The company maintained a stable gross profit margin of 16.2% while managing higher sales and marketing expenses. The successful IPO in October provided additional capital, supporting future growth and strategic initiatives.